Payment overview · 2025
General Payments
$1,462.40
59 reported records · 12 companies
Healthcare provider profile · identity verified
Larry M Walker, MD
Allopathic & Osteopathic Physicians|Family Medicine · MEMPHIS, TN · NPI 1437122355
Verified facts
What the public records show
CMS Open Payments records show Larry M Walker, MD received $1,462.40 in general payments during 2025 across 59 reported records.
Novo Nordisk Inc accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $345.08 | 23.6% | 22 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $263.19 | 18.0% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $247.83 | 16.9% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $151.39 | 10.3% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $92.44 | 6.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.50 | 5.8% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $84.49 | 5.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.08 | 4.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.72 | 2.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.45 | 2.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.65 | 1.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.58 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,462.40 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $345.08 | 22 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $263.19 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $227.86 | 21 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $192.74 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $117.29 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $117.29 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $92.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.50 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $84.49 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $55.09 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $40.45 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.10 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 154 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 147 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 53 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
147 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 526 | 222 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 234 |
| Losartan Potassium | Losartan Potassium | 273 | 118 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 236 | 129 |
| Potassium Chloride | Potassium Chloride | 227 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 81 |
| Furosemide | Furosemide | 181 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 181 | 83 |
| Hydralazine Hcl | Hydralazine Hcl | 178 | 76 |
| Omeprazole | Omeprazole | 166 | 79 |
| Gabapentin | Gabapentin | 164 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 90 |
| Jardiance | Empagliflozin | 154 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 73 |
| Metformin Hcl Er | Metformin Hcl | 150 | 71 |
| Mounjaro | Tirzepatide | 147 | 37 |
| Allopurinol | Allopurinol | 143 | 59 |
| Lorazepam | Lorazepam | 143 | 25 |
| Ozempic | Semaglutide | 143 | 45 |
| Alendronate Sodium | Alendronate Sodium | 127 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 122 | 13 |
| Nifedipine Er | Nifedipine | 121 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 109 | 55 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 19 |
| Eliquis | Apixaban | 96 | 32 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 48 |
| Prednisone | Prednisone | 92 | 39 |
| Pregabalin | Pregabalin | 91 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 41 |
| Carvedilol | Carvedilol | 88 | 44 |
| Azithromycin | Azithromycin | 85 | 70 |
| Trulicity | Dulaglutide | 84 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 37 |
| Metformin Hcl | Metformin Hcl | 75 | 36 |
| Simvastatin | Simvastatin | 72 | 33 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 71 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 32 |
| Meloxicam | Meloxicam | 66 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 61 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 60 | 22 |
| Lisinopril | Lisinopril | 59 | 28 |
| Methylprednisolone | Methylprednisolone | 59 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 20 |
| Amoxicillin | Amoxicillin | 58 | 46 |
| Atenolol | Atenolol | 57 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 45 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 20 |
| Sertraline Hcl | Sertraline Hcl | 48 | 19 |
| Chlorthalidone | Chlorthalidone | 47 | 24 |
| Glimepiride | Glimepiride | 46 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 22 |
| Valsartan | Valsartan | 44 | 17 |
| Fluconazole | Fluconazole | 43 | 25 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 43 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 40 | 26 |
| Ezetimibe | Ezetimibe | 39 | 21 |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Famotidine | Famotidine | 37 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 24 |
| Linzess | Linaclotide | 35 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 14 |
| Trazodone Hcl | Trazodone Hcl | 34 | 17 |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | 12 |
| Ibuprofen | Ibuprofen | 32 | 20 |
| Colchicine | Colchicine | 31 | 19 |
| Hydrocortisone | Hydrocortisone | 31 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 15 |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | 17 |
| Farxiga | Dapagliflozin Propanediol | 29 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | 11 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | 11 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 26 | 24 |
| Meclizine Hcl | Meclizine Hcl | 26 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | 11 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 19 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Clarithromycin | Clarithromycin | 24 | 20 |
| Finasteride | Finasteride | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | 13 |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 15 |
| Glipizide | Glipizide | 21 | 12 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | 13 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | 11 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Febuxostat | Febuxostat | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | 13 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Naproxen | Naproxen | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,462.40 · 59 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ENROUTE Transcarotid Neuroprotection System, FREESTYLE LIBRE, FREESTYLE LIBRE 3, JARDIANCE, LINZESS, MOUNJARO, Omnipod, Ozempic, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error